flesinoxan has been researched along with slv 313 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ashby, CR; Feenstra, RW; Glennon, JC; Herremans, AH; Hesselink, MB; Kruse, CG; Li, Z; Long, SK; McCreary, AC; Meltzer, HY; Reinders, JH; van Stuivenberg, H | 1 |
1 other study(ies) available for flesinoxan and slv 313
| Article | Year |
|---|---|
SLV313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4- [5-(4-fluoro-phenyl)-pyridin-3-ylmethyl]-piperazine monohydrochloride): a novel dopamine D2 receptor antagonist and 5-HT1A receptor agonist potential antipsychotic drug.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Behavior, Animal; Binding, Competitive; Brain Chemistry; Catalepsy; CHO Cells; Columbidae; Cricetinae; Cricetulus; Discrimination, Psychological; Disease Models, Animal; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Humans; Male; Piperazines; Rats; Rats, Wistar; Serotonin 5-HT1 Receptor Agonists; Serotonin Receptor Agonists; Transfection | 2007 |